Skip to main content
Federal Practitioner
FULL MENU
Close Menu
Federal Practitioner
CE/CME
Cardiology
Diabetes
Federal News
Government and Regulations
Health Policy
News
Journal
Digital Edition/App
Current Regular Issue
Current Special Issue
Past Issues
Submission Guidelines
Mental Health
Oncology
AVAHO Updates
Breast Cancer
Colon and Rectal
Hematologic Malignancies
Lung Cancer
Oncology
Prostate Cancer
Pharmacology
Women's Health
Pharmacology
Peginterferon Alfa-2a Plus Ribavirin for HCV: How Long and How Much?
Fed Pract
. 2004 June;21(6):33
PDF Download
Next Article:
The Hepatitis C Clinic
Hepatitis
Close
MDedge Home
Diseases & Conditions
Depression
Diabetes
Hepatitis
HIV
Long COVID
Obesity
Pain
PTSD
Stroke
Traumatic Brain Injury
Hematology and Oncology
AVAHO Updates
Breast Cancer
Colon and Rectal
Hematologic Malignancies
Lung Cancer
Oncology
Prostate Cancer
Specialties
Addiction Medicine
Cardiology
Dermatology
Geriatrics
Mental Health
Neurology
Orthopedics
Pharmacology
Pulmonology
Sexual Health
Sleep Medicine
Trauma
Vaccines
Women's Health
Federal News
Government and Regulations
Health Policy
News
Original Articles
Case Reports
Original Research
Reviews
Best Practices
Clinical Review
Perspectives
Commentary
Q&A
Diversity in Medicine
Explore
Multimedia
Explore
Audio
Video
Blood & Cancer podcast
Dermatology Weekly podcast
Psychcast podcast
All MDedge podcasts
News
Explore
News by Conference
Expert Interview
For Residents
Quizzes
Explore
MD-IQ
CME Supplements
ReCAP
Conference ReCAP
Supplements
Sponsored Content
Explore
Treatment of Veterans With Metastatic Hormone-Sensitive Prostate Cancer
Research Summaries
Explore
Clinical Edge Journal Scan
Roundtables
CE/CME
Submission Guidelines
Subscribe to Federal Practitioner
Treatment of Veterans With Metastatic Hormone-Sensitive Prostate Cancer
Medical Directors / Pharmacy Directors
Nurse Practitioners / Physician Assistants
Residents
VA / DoD / PHS
More
AVAHO Updates
Digital Edition/App
